Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 6, 2008

Regulus Licenses miRNA Antagonist IP from Stanford University

  • Regulus Therapeutics obtained exclusive rights from Stanford University to worldwide patent applications covering methods and compositions for antagonizing miR-181a to regulate immune responses. Changes in miR-181a levels have been shown to modify the response of immune cells such as T lymphocytes to specific stimuli. Additionally, its antagonism could lead to a new way to treat inflammatory diseases, according to the company.

    Research recently published by scientists at Stanford University and Alnylam demonstrated that modulation of miR-181a levels in an immune cell modified the sensitivity of the cell to specific stimuli.

    The team found that by increasing expression of miR-181a, an increase in the immune cell’s response to an inflammatory stimulus occurred. Conversely, decreasing levels of miR-181a in the immune cell led to a diminution in the cell’s response to an inflammatory stimulus, thereby desensitizing the cell to the stimulus.

    Using a selective miRNA antagonist to inhibit miR-181a function resulted in efficient reduction in the immune cell’s response to a stimulus. This data suggests that controlling miR-181a levels with selective antagonists may lead to a novel approach to treating inflammatory diseases.

    “We are excited about obtaining exclusive rights to this intellectual property, as it is another step in Regulus’ overall strategy to build a broad and leading platform of technology and intellectual property for the development of miRNA therapeutics,” remarks Kleanthis G. Xanthopoulos, Ph.D., president and CEO. Less than a year ago, Regulus was created as a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »